GLP-2: mechanism and role
Glucagon-like peptide-2 (GLP-2) is a proglucagon-derived peptide secreted by intestinal L-cells. It's studied mainly for intestinal growth, mucosal repair, and nutrient absorption — contexts like short bowel syndrome. That's a completely different research lane from the metabolic/weight research surrounding GLP-1.
GLP-1 vs. GLP-2: the most common mix-up
GLP-1 and GLP-2 share a precursor protein (proglucagon) and near-identical names, but act on entirely different receptors. GLP-1 is the one dominating headlines right now — semaglutide, tirzepatide, and retatrutide are all GLP-1-pathway (or GLP-1/GIP/glucagon multi-agonist) compounds studied for metabolic and weight research. If that's what brought you here, you're one letter off — see below.
Related analogs often studied alongside GLP-2
The broader incretin-research family includes dual and triple agonists combining GLP-1 receptor activity with GIP and/or glucagon activity. One of them — a dual GLP-1/GIP receptor agonist, also referenced in research catalogs as GLP-2-T — is the compound most people searching "GLP-2" in a weight-research context are actually after.
Why people research this class of compound
Weight-management and metabolic health research drive almost all of the interest here, on the back of the last few years of GLP-1-class treatment coverage. That coverage pulled in a far wider audience than the specialized researchers who first studied these receptor pathways — which is exactly why the GLP-1/GLP-2 name mix-up has become so common.
GLP-2-T (dual GLP-1/GIP agonist), ≥99% purity, independent COA on every lot.
Reading a certificate of analysis (COA)
A trustworthy COA states the testing method (HPLC and mass spectrometry), the measured purity percentage, the lot number, and the identity of the testing lab. Always cross-check the lot number on the vial against the published COA.